Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group.

@article{Rao2011PhaseID,
  title={Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group.},
  author={Ruta D Rao and Melody A. Cobleigh and Robert Gray and Mark L. Graham and Larry Norton and Silvana Martino and George Thomas Budd and James N. Ingle and William C. Wood},
  journal={Medical oncology},
  year={2011},
  volume={28 Suppl 1},
  pages={S39-47}
}
Fenretinide and tamoxifen have additive antitumor effects preclinically. We performed a randomized, placebo-controlled, double-blind adjuvant trial in breast cancer patients treated for 5 years with tamoxifen, with or without fenretinide. Between October 1995 and October 1999, 426 postmenopausal women with hormone receptor-positive breast cancer were randomized. Patients were monitored for efficacy and toxicity. Four hundred and nineteen patients were evaluable. The study was terminated early… CONTINUE READING

From This Paper

Figures and tables from this paper.

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology • 2001

Similar Papers

Loading similar papers…